<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994149</url>
  </required_header>
  <id_info>
    <org_study_id>Bio-REB #08-151</org_study_id>
    <secondary_id>HC Control Number: 126963</secondary_id>
    <nct_id>NCT00994149</nct_id>
  </id_info>
  <brief_title>Diazoxide In the Management Of Hypoglycemic Neonates</brief_title>
  <acronym>DIMOHN</acronym>
  <official_title>Use for Diazoxide in the Initial Management of Hypoglycemia in Infants of Diabetic Mothers and Infants Large for Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diazoxide is an oral hyperglycemic medication. Diazoxide has been proven effective for
      treating hypoglycemia in infants and children with some types of persistent hyperinsulinemic
      hypoglycemia. The mechanism of action results in decreased insulin secretion. One of the
      causes of hypoglycemia in infants of diabetic mothers occurs due to a transient
      hyperinsulinemic state postnatally. The investigators have clinical experience and success
      using diazoxide in their unit for patients with hypoglycemia not adequately managed with
      intravenous (iv) dextrose and enteral supplementation. In this randomized controlled study
      the investigators expect that by using diazoxide as the initial treatment for infants of
      diabetic mothers with asymptomatic hypoglycemia (blood glucose of 2.5 to 2.0mmol/L), the
      investigators will be able to decrease the number of infants requiring an intravenous by at
      least thirty percent.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose measurement less than 2.0mmol/L</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of infants with significantly low blood glucose measurements (&lt;1.5mmol/L).</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay for infants in hospital</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for intravenous dextrose infusion to maintain blood glucose above 2.0mmol/L</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to neonatal intensive care unit (NICU)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombocytopenia and/or Leukopenia</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolyte imbalance requiring clinical intervention (intravenous or oral)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infant, Newborn, Diseases</condition>
  <condition>Pregnancy in Diabetics</condition>
  <condition>Infant, Diabetic Mother</condition>
  <condition>Hypoglycemia</condition>
  <condition>Infant, Large for Gestational Age</condition>
  <arm_group>
    <arm_group_label>Diazoxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants in this are will receive 10mg/kg/d of diazoxide divided and given every eight hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ora-plus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Liquid suspension modified to match intervention. Given every eight hours. Provided in shielded syringes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide</intervention_name>
    <description>10mg/kg/d divide every 8 hours</description>
    <arm_group_label>Diazoxide</arm_group_label>
    <other_name>Brand Name: Proglycem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ora-plus</intervention_name>
    <description>placebo, give every 8 hours.</description>
    <arm_group_label>Ora-plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants of diabetic mothers (IDMs) or infants weighing &gt;90%

          -  Hypoglycemia: two consecutive blood glucose measurements &lt;2.6mol/L and &gt;1.9mmol/L in
             the first twelve hours of life

          -  &gt; 36 weeks gestational age

        Exclusion Criteria:

          -  Infants with symptomatic hypoglycemia (regardless of value

          -  Infants who meet criteria for intravenous dextrose according to the Canadian Pediatric
             Society (CPS) position statement

          -  Infants with contraindications for enteral feeds and/or medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koravangattu Sankaran, MD, BS, FRCPC, F.C.C.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan, Department of Pediatrics, Head of Neonatal Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Koravangattu Sankaran, MD, BS, FRCPC, F.C.C.M.</last_name>
    <phone>1-306-966-8118</phone>
    <email>k.sankaran@usask.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer M Toye, MD, FRCP(C)</last_name>
    <phone>1-306-966-8118</phone>
    <email>jtoye13@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Koravangattu Sankaran, MD, FRCPC</last_name>
      <phone>1-306-966-8118</phone>
      <email>k.sankaran@usask.ca</email>
    </contact>
    <contact_backup>
      <last_name>Carmen Dmytryshyn, RN</last_name>
      <phone>1-306-966-8138</phone>
    </contact_backup>
    <investigator>
      <last_name>Koravangattu Sankaran, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Screening guidelines for newborns at risk for low blood glucose. Paediatr Child Health. 2004 Dec;9(10):723-740. English, French, English.</citation>
    <PMID>19688086</PMID>
  </reference>
  <reference>
    <citation>Stenninger E, Flink R, Eriksson B, Sahl√®n C. Long-term neurological dysfunction and neonatal hypoglycaemia after diabetic pregnancy. Arch Dis Child Fetal Neonatal Ed. 1998 Nov;79(3):F174-9.</citation>
    <PMID>10194986</PMID>
  </reference>
  <reference>
    <citation>Holtrop PC. The frequency of hypoglycemia in full-term large and small for gestational age newborns. Am J Perinatol. 1993 Mar;10(2):150-4.</citation>
    <PMID>8476480</PMID>
  </reference>
  <reference>
    <citation>Cornblath M, Hawdon JM, Williams AF, Aynsley-Green A, Ward-Platt MP, Schwartz R, Kalhan SC. Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds. Pediatrics. 2000 May;105(5):1141-5. Review.</citation>
    <PMID>10790476</PMID>
  </reference>
  <reference>
    <citation>Diwakar KK, Sasidhar MV. Plasma glucose levels in term infants who are appropriate size for gestation and exclusively breast fed. Arch Dis Child Fetal Neonatal Ed. 2002 Jul;87(1):F46-8.</citation>
    <PMID>12091291</PMID>
  </reference>
  <reference>
    <citation>Hoseth E, Joergensen A, Ebbesen F, Moeller M. Blood glucose levels in a population of healthy, breast fed, term infants of appropriate size for gestational age. Arch Dis Child Fetal Neonatal Ed. 2000 Sep;83(2):F117-9.</citation>
    <PMID>10952705</PMID>
  </reference>
  <reference>
    <citation>Hawdon JM. Hypoglycaemia and the neonatal brain. Eur J Pediatr. 1999 Dec;158 Suppl 1:S9-S12. Review.</citation>
    <PMID>10592092</PMID>
  </reference>
  <reference>
    <citation>Stenninger E, Schollin J, Aman J. Early postnatal hypoglycaemia in newborn infants of diabetic mothers. Acta Paediatr. 1997 Dec;86(12):1374-6.</citation>
    <PMID>9475319</PMID>
  </reference>
  <reference>
    <citation>Nold JL, Georgieff MK. Infants of diabetic mothers. Pediatr Clin North Am. 2004 Jun;51(3):619-37, viii. Review.</citation>
    <PMID>15157588</PMID>
  </reference>
  <reference>
    <citation>DRASH A, WOLFF F. DRUG THERAPY IN LEUCINE-SENSITIVE HYPOGLYCEMIA. Metabolism. 1964 Jun;13:487-92.</citation>
    <PMID>14193979</PMID>
  </reference>
  <reference>
    <citation>Agrawal RK, Lui K, Gupta JM. Neonatal hypoglycaemia in infants of diabetic mothers. J Paediatr Child Health. 2000 Aug;36(4):354-6.</citation>
    <PMID>10940170</PMID>
  </reference>
  <reference>
    <citation>Tyrrell VJ, Ambler GR, Yeow WH, Cowell CT, Silink M. Ten years' experience of persistent hyperinsulinaemic hypoglycaemia of infancy. J Paediatr Child Health. 2001 Oct;37(5):483-8.</citation>
    <PMID>11885714</PMID>
  </reference>
  <reference>
    <citation>Touati G, Poggi-Travert F, Ogier de Baulny H, Rahier J, Brunelle F, Nihoul-Fekete C, Czernichow P, Saudubray JM. Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria. Eur J Pediatr. 1998 Aug;157(8):628-33.</citation>
    <PMID>9727845</PMID>
  </reference>
  <reference>
    <citation>Dunne MJ, Cosgrove KE, Shepherd RM, Aynsley-Green A, Lindley KJ. Hyperinsulinism in infancy: from basic science to clinical disease. Physiol Rev. 2004 Jan;84(1):239-75. Review.</citation>
    <PMID>14715916</PMID>
  </reference>
  <reference>
    <citation>Shirland L. When it is more than transient neonatal hypoglycemia: hyperinsulinemia--a case study challenge. Neonatal Netw. 2001 Jun;20(4):5-11. Review.</citation>
    <PMID>12143902</PMID>
  </reference>
  <reference>
    <citation>Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 14th edition. Hudson (OH): Lexi-comp, Inc. 2007: 485-6</citation>
  </reference>
  <reference>
    <citation>McGraw ME, Price DA. Complications of diazoxide in the treatment of nesidioblastosis. Arch Dis Child. 1985 Jan;60(1):62-4.</citation>
    <PMID>3970573</PMID>
  </reference>
  <reference>
    <citation>Behrman RE, Kliegman R, Jenson HB, StantonBF. Nelson Textbook of Pediatrics 18th Edition. Philadelphia: WB Saunders Company 2007:783-6</citation>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>October 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>October 10, 2009</last_update_submitted>
  <last_update_submitted_qc>October 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Koravangattu Sankaran</name_title>
    <organization>University of Saskatchewan, Department of Pediatrics, Neonatal Research Group</organization>
  </responsible_party>
  <keyword>Infants of Diabetic Mothers</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Diazoxide</keyword>
  <keyword>Large for Gestation Infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
    <mesh_term>Fetal Macrosomia</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diazoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

